Scientists have found a way to store hundreds of terabytes of data onto a tiny crystal, with plans to scale this up to a disc ...

Institutional peer review led to recommended changes in more than one-quarter of radiotherapy treatment plans, according to ...

Q4 2024 Earnings Call Transcript March 13, 2025 Cellectar Biosciences, Inc. beats earnings expectations. Reported EPS is ...

Lu rhPSMA-10.1 showed high tumor radiation with low healthy tissue exposure in a phase 1/2 trial for metastatic ...

LUND, SE / ACCESSWIRE / March 04, 2025 / Spago Nanomedical (STO:SPAGO.ST) (FRA:7UX.F) Spago Nanomedical AB (publ) announced today that the independent Data Monitoring Committee (DMC) recommends a dose ...

Blazars are active galaxies that emit narrow jets of ionised matter from their centres, aimed towards Earth. Depending on ...

IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and leading provider of proton therapy solutions for the treatment of cancer, today announces it has ...

Q4 2024 Earnings Call Transcript March 7, 2025 Operator: Good morning, and welcome to the Molecular Partners Fourth Quarter ...

Targeted alpha therapy shows promise in treating neuroendocrine tumours, offering hope where beta therapies fall short.

Sensus Healthcare (NASDAQ:SRTS – Get Free Report) had its price objective cut by equities research analysts at Lake Street Capital from $18.00 to $13.00 in a report issued on Tuesday,Benzinga reports.

Learn more about whether Mirion Technologies, Inc. or Plexus Corp. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

This article is part of a Festschrift commemorating Dr Seymour Reichlin. His work on neuroendocrinology laid the ground for theranostics–such as TAT that blend diagnostics and therapeutics. Now 100 ...